the relationship between different assays for detection and quantification of amyloid beta 42 in human cerebrospinal fluid
Clicks: 174
ID: 251207
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
174 views
33 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #31 of 40 articles by views in advanced biomedical research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Alzheimer's disease (AD), which is characterized by a degeneration of neurons and their synapses, is one of the most common forms of dementia. CSF levels of amyloid 𝛽42 (A𝛽42) have been recognized as a strong candidate to serve as an AD biomarker. There are a number of commercial assays that are routinely employed for measuring A𝛽42; however, these assays give diverse ranges for the absolute levels of CSF A𝛽42. In order to employ CSF A𝛽42 as a biomarker across multiple laboratories, studies need to be performed to understand the relationship between the different platforms. We have analyzed CSF samples from both diseased and nondiseased subjects with two different widely used assay platforms. The results showed that different values for the levels of CSF A𝛽42 were reported, depending on the assay used. Nonetheless, both assays clearly demonstrated statistically significant differences in the levels of A𝛽42 in CSF from AD relative to age-matched controls (AMC). This paper provides essential data for establishing the relationship between these assays and provides an important step towards the validation of A𝛽42 as a biomarker for AD.
| Reference Key |
ellis2012internationalthe
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Teresa A. Ellis;Jinhe Li;David LeBlond;Jeffrey F. Waring |
| Journal | advanced biomedical research |
| Year | 2012 |
| DOI |
10.1155/2012/984746
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.